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Acute Lymphoblastic leukemia
Introduction
Asparaginase is a key component of the treatment of acute
lymphoblastic leukemia (ALL). Many studies have shown that
intensification of asparaginase treatment is essential to improve
event-free survival of children with ALL.1-5 However, the use of
asparaginase is associated with multiple toxicities including
thrombosis, pancreatitis, hyperammonemia, central neurotoxi-
city and, relatively commonly, hypertriglyceridemia and hyper-
cholesterolemia (dyslipidemia). Although these are well-
known side effects, the incidence and natural course of dyslipi-
demia during very prolonged treatment with PEGasparaginase
or Erwinia asparaginase are unknown. It is also unclear whether
asparaginase therapy should be interrupted or stopped if these
toxic effects occur and whether the different toxicities are relat-
ed to levels of asparaginase activity.
We, therefore, analyzed the incidence of dyslipidemia and
its natural course during very prolonged courses of
PEGasparaginase or Erwinia asparaginase in children with
ALL. We also prospectively studied other asparaginase-asso-
ciated toxicities, such as pancreatitis, hyperammonemia,
thrombosis and central neurotoxicity, and their relationship
to asparaginase activity.
Methods
Patients and the ALL-10 treatment protocol
From July 2009 untill October 2012, ALL-10 medium-risk patients
from two pediatric oncology centers (Rotterdam and Groningen, the
Netherlands) were entered into this study. The Institutional Review
Board approved this study before the patients were enrolled. Informed
consent was obtained from parents or their guardians and from
patients ≥12 years of age. This study was conducted in accordance
with the Declaration of Helsinki.
All patients received eight doses of native E.coli asparaginase (5,000
IU/m2 per dose) every 3 days in induction. The intensification/contin-
uation phase of the ALL-10 medium-risk treatment included
PEGasparaginase as the first-line agent (2,500 IU/m2 per dose) every 2
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We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia dur-
ing very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lym-
phoblastic leukemia. We also evaluated the incidence of pancreatitis, thrombosis, hyperammonemia and central
neurotoxicity and their association with asparaginase activity levels. Eighty-nine patients were treated according
to the Dutch Childhood Oncology Group Acute Lymphoblastic Leukemia 10 medium-risk intensification proto-
col, which includes 15 doses of PEGasparaginase (2,500 IU/m2) over 30 weeks. Erwinia asparaginase (20,000 IU/m2)
was administered when allergy to or silent inactivation of PEGasparaginase occurred. Triglyceride, cholesterol and
ammonia levels increased rapidly in children treated with PEGasparaginase and remained temporarily elevated,
but normalized after administration of the last asparaginase dose. Among the patients treated with
PEGasparaginase, hypertriglyceridemia and hypercholesterolemia (grade 3/4) were found in 47% and 25%,
respectively. The correlation between PEGasparaginase activity levels and triglyceride levels was strongest at week
5 (Spearman correlation coefficient=0.36, P=0.005). The triglyceride levels were higher in children ≥10 years old
than in younger patients (<10 years old) after adjustment for type of asparaginase preparation: median 4.9 mmol/L
versus 1.6 mmol/L (P<0.001). In patients receiving Erwinia asparaginase, triglyceride levels increased in the first
weeks as well, but no grade 3/4 dyslipidemia was found. Hyperammonemia (grade 3/4) was only found in patients
treated with Erwinia asparaginase (9%). Thrombosis occurred in 4.5%, pancreatitis in 7%, and central neurotoxi-
city in 9% of patients using either of the two agents; these toxicities were not related to levels of asparaginase
activity or to triglyceride levels. In conclusion, severe dyslipidemia occurred frequently, but was temporary and
was not associated with relevant clinical events and should not, therefore, be considered a reason for modifying
asparaginase treatment. Dyslipidemia was the only toxicity related to levels of asparaginase activity.
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ABSTRACT
weeks for a total of 15 doses (Online Supplementary Figure S1). In
case of an allergy to or silent inactivation of PEGasparaginase, the
patient was switched to Erwinia asparaginase as the second-line
agent (20,000 IU/m2 per dose) 2-3 times per week to complete 30
weeks of asparaginase therapy. In the case of high asparaginase
activity levels (72 hours ≥100 U/L), the frequency of Erwinia
asparaginase infusions was reduced to twice weekly.6 Both
asparaginase preparations were administered intravenously over 1
hour.
Study design and definitions 
For practical reasons, the measurements of triglyceride, total
cholesterol, and ammonia were non-fasting. Blood samples were
taken at week 1 (baseline), weeks 3, 5, 7, 9, 15 and 25 during the
intensification phase including asparaginase and week 37, 8 weeks
after the final PEGasparaginase or 6 weeks after the final Erwinia
asparaginase infusion. 
Hypertriglyceridemia, hypercholesterolemia, hyperammone-
mia, pancreatitis, thrombosis and central neurotoxicity were grad-
ed prospectively according to the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE) ver-
sion 3.0. Cholesterol levels were designated grade 3 if they were
between 10.34-12.92 mmol/L and grade 4 if they were greater
than 12.92 mmol/L. Triglyceride levels were defined as grade 3 if
they were between five to ten times the upper limit of normal (1.0
mmol/L) and grade 4 if they were more than ten times higher than
the upper limit of normal. Thrombosis was scored only if it was
not related to a central venous line. To study the relation between
ammonia level and central neurotoxicity, we prospectively collect-
ed central neurotoxicity items on structured case record forms
assessed by the pediatric oncologists. These items were ataxia,
somnolence or depressed level of consciousness, mood alteration
and seizures. Central neurotoxicity included posterior reversible
encephalopathy syndrome which was not mentioned in the
CTCAE.
Allergy was also graded according to the NCI CTCAE version
3.0. Definitions of silent inactivation of PEGasparaginase and
Erwinia asparaginase were previously described.6 In total 22
patients were switched to Erwinia asparaginase to complete 30
weeks of asparaginase therapy; two patients had an allergic reac-
tion to the first PEGasparaginase dose and 18 patients showed an
allergic reaction to the second dose, all these patients were
switched to Erwinia asparaginase. The remaining two patients had
silent inactivation of PEGasparaginase which was detected in real-
time and were switched to Erwinia asparaginase after the second
PEGasparaginase dose. 
Laboratory measurements
Asparaginase activity levels were processed and assessed as
described earlier.7 Triglyceride, cholesterol, and ammonia levels
were analyzed in both medical centers. Samples for ammonia lev-
els were put in an ice bath and were immediately processed at the
laboratory.
Statistical analysis
The data were analyzed with the software packages SPSS for
Windows version 20.0 (IBM Corp., Armonk, NY, USA) and
GraphPad Prism version 5.01 (GraphPad Prism Inc., San Diego,
CA, USA). 
Changes of triglyceride, cholesterol, and ammonia levels over
time were evaluated using mixed models analysis of variance
(ANOVA). Changes related to age and gender were also investigat-
ed using mixed models ANOVA. All analyses were done after log-
transformation of measured values to get approximate normal dis-
tributions. Mean values were estimated by backtransforming the
mean of log-values. 
The incidence of toxicities (pancreatitis, thrombosis, central
neurotoxicity) related to treatment (PEGasparaginase or Erwinia
asparaginase) was investigated with Fisher exact tests. Spearman
correlation coefficients were used to evaluate the relations
between triglyceride, cholesterol and asparaginase activity levels.
A two-sided P-value < 0.05 was considered statistically significant.
Data are presented as mean ± standard error of the mean (SEM) or
specified otherwise.
Results
Characteristics and toxicity of asparaginase 
preparations
We enrolled 89 patients (49% boys). The median age
was 4.9 years (range, 1.2-16.2 years), 78 (88%) patients
had precursor B-ALL and 11 (12%) patients had T-ALL.
Twenty-two out of 89 (25%) patients were switched to
Erwinia asparaginase because of either allergy to or silent
inactivation of PEGasparaginase. 
Table 1 summarizes the toxicity data. Four patients
developed severe pancreatitis during PEGasparaginase and
two patients during Erwinia asparaginase; these patients
discontinued asparaginase permanently. No grade 3/4 dys-
lipidemia was found in patients receiving Erwinia asparag-
inase. However, hypertriglyceridemia and hypercholes-
terolemia grade 3/4 were found in 47% and 25%, respec-
tively, of the patients treated with PEGasparaginase. 
Hyperammonemia grade 3/4 occurred in two patients
(9%) treated with Erwinia asparaginase, but in none of the
patients treated with PEGasparaginase.
Two patients receiving PEGasparaginase and two other
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Table 1. Toxicity of PEGasparaginase and Erwinia asparaginase.
PEGasparaginase (n=67) Erwinia asparaginase (n=22) P
Grades 1/2 Grades 3/4 Grades 1/2 Grades 3/4
n % n % n % n %
Pancreatitis 0 0 4 6 1 5 2 9 ns
Hypertriglyceridemia 15 22 31 47 7 32 0 0 P<0.001
Hypercholesterolemia 6 9 17 25 8 37 0 0 P=0.01
Hyperammonemia 34 51 0 0 9 41 2 9 ns
Thrombosis* 0 0 2 3 0 0 2 9 ns
Central neurotoxicity 0 0 7 10 0 0 1 5 ns
*not related to vascular access.  P-values are given for the comparisons of grade 3/4 toxicities between PEGasparaginase versus Erwinia asparaginase.  ns: not significant.
patients receiving Erwinia asparaginase developed throm-
bosis. There was no standard policy to evaluate the coag-
ulation pattern during asparaginase therapy and none of
the patients received prophylactic treatment.
Asparaginase therapy was stopped in these four patients
and reintroduced again after 3 or 4 weeks with low molec-
ular weight heparin therapy for at least 3 months and pro-
phylaxis thereafter until finishing asparaginase therapy.
No recurrence of thrombosis was seen thereafter. 
Central neurotoxicity grade 3/4 occurred in 10% of
patients treated with PEGasparaginase and in 5% of those
treated with Erwinia asparaginase. Central neurotoxicity
included somnolence or seizures (grade 3/4) or posterior
reversible encephalopathy syndrome.
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Figure 1. Serum triglyceride, and cholesterol levels over time (mean ± SEM) and relations to serum asparaginase activity.  Triglyceride levels
(A) and cholesterol levels (B) during PEGasparaginase therapy, triglyceride levels (C) and cholesterol levels (D) during Erwinia asparaginase
therapy. Mean ± SEM.  Association between triglyceride and asparaginase activity (E) and association between cholesterol and asparaginase
activity (F). The dotted lines in panels (B) and (D) represent the upper and lower limits of normal. The dotted line in panels (A) and (C) represent
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No difference was found between PEGasparaginase and
Erwinia asparaginase for any of the grade 3/4 toxicities
(pancreatitis, thrombosis, central neurotoxicity) (all
P>0.27).
Clinical course of dyslipidemia and associations
with asparaginase activity
Serum triglyceride and cholesterol levels were measured
in 380 samples from 67 children on PEGasparaginase and
140 samples from the remaining children on Erwinia
asparaginase. In total 460 samples were scheduled for the
children on PEGasparaginase, so in 83% of the patients a
sample was successfully obtained. In total 161 samples
should have been obtained from the children on Erwinia
asparaginase, leading to a similar percentage of successful-
ly obtained samples.
The median triglyceride level was 0.8 mmol/L (upper
limit of normal: 1 mmol/L) and the median cholesterol
level was 3.7 mmol/L (upper limit of normal: 5 mmol/L) at
the start of therapy intensification. Figure 1A shows that
after the first and second PEGasparaginase infusions, at
weeks 3 and 5, there was a significant increase in mean
triglyceride levels (P<0.001). From week 5 until the last
PEGasparaginase infusion was given, triglyceride levels
remained high and no significant changes were seen.
Cholesterol levels increased significantly (P<0.001) during
the first 9 weeks of PEGasparaginase therapy and
remained stable thereafter (Figure 1B). By week 37, the
triglyceride and cholesterol levels had normalized in all
patients.  
The median triglyceride level was 1.3 mmol/L and the
median cholesterol level was 4.3 mmol/L at the start of
administration of Erwinia asparaginase. Figure 1C shows
that in the first 2 weeks after starting Erwinia asparaginase
the triglyceride level increased, but not significantly.
Thereafter, the mean triglyceride levels remained stable
and normalized by week 37, after the final Erwinia
asparaginase infusion. Cholesterol levels were within the
normal range during and after Erwinia asparaginase thera-
py (Figure 1D). 
In one child with extreme hypertriglyceridemia during
PEGasparaginase treatment, dexamethasone was tem-
porarily omitted. Another child with extreme hyper-
triglyceridemia was already successfully managed by tem-
porarily omitting dexamethasone, as described
previously.8 Asparaginase courses were not discontinued
in any of the patients with dyslipidemia, and 30 weeks of
asparaginase exposure were completed without any other
interventions. 
It should be noted that the levels of PEGasparaginase
activity were much higher than those of Erwinia asparagi-
nase activity. Previously, we reported that the trough
activity for PEGasparaginase (dose of 2,500 IU/m2; once
every 2 weeks) was 899 U/L and that for Erwinia asparag-
inase (dose of 20,000 IU/m2; 2-3 times per week) was 157
U/L. Figure 1E,F shows that high triglyceride and choles-
terol levels were associated with high levels of asparagi-
nase activity. Studying the correlations between
PEGasparaginase activity and triglyceride levels at the var-
ious treatment weeks, it was seen that the correlation was
strongest at week 5 (Spearman correlation coefficient =
0.36, P=0.005). The correlation between PEGasparaginase
activity and cholesterol levels was strongest at week 9
(Spearman correlation coefficient = 0.35, P=0.01).
Using mixed model analysis, it was found that the
triglyceride levels of children ≥10 years old were higher
than those of younger patients (<10 years) after adjusting
for asparaginase preparations: median 4.9 mmol/L versus
1.6 mmol/L (P<0.001). The same held true for cholesterol
levels, with median values of 6.2 mmol/L versus 4.2
mmol/L in the older and younger children, respectively
(P<0.001).
Clinical course of ammonia levels and toxicities 
(pancreatitis, thrombosis, central neurotoxicity)
Ammonia levels were measured in 326 samples from 67
children on PEGasparaginase and 102 samples from the
remaining children on Erwinia asparaginase. In total 460
samples were scheduled for the children on
PEGasparaginase, so a sample was successfully obtained
from 71% of the patients. In total 161 samples should
have been obtained from the children on Erwinia asparag-
inase, leading to a similar percentage of successfully
obtained samples.
Figure 2A,B shows the mean ammonia levels during
PEGasparaginase or Erwinia asparaginase therapy along
time. A rapid increase in ammonia levels was observed
after the first asparaginase infusions (upper limit of nor-
mal: 40 mM). The ammonia levels normalized in all
patients by week 37. As far as concerns the incidence of
central neurotoxicity, we analyzed the relation with
ammonia levels and asparaginase activity using time-
dependent Cox regression. We also used Cox regression to
analyze the relation of pancreatitis and thrombosis with
Toxicity of very intensified PEGasparaginase and Erwinia asparaginase
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Figure 2. Ammonia levels over time (mean ± SEM) during therapy
with (A) PEGasparaginase and (B) Erwinia asparaginase (mean ±
SEM). The dotted line in panels (A) and (B) represents the upper limit
of normal; as the lower limit of normal is 0 mM this line is not shown.
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triglyceride levels and asparaginase activity. The results of
these analyses are shown in Online Supplementary Figure
S2A-F. No significant relations were found between levels
of asparaginase activity in the serum and the occurrence of
pancreatitis, thrombosis or central neurotoxicity or
between triglyceride levels and these toxicities.
Discussion
Our study showed that 7% of the patients developed
pancreatitis and 4.5% developed thrombosis when receiv-
ing very prolonged courses of asparaginases. Recently, the
Dana Farber Consortium Institute group reported a compa-
rable incidence of pancreatitis (5%) and thrombosis (8%)
with the same schedule.9 We demonstrate that high levels
of asparaginase activity are related to hypertriglyceridemia
and hypercholesterolemia (dyslipidemia). It should be
noted that PEGasparaginase activity levels were much
higher than Erwinia asparaginase activity levels. An impor-
tant observation is that dyslipidemia, even grade 3/4, is
temporary and is not associated with clinically relevant
events and should not, therefore, be considered a reason
for modifying asparaginase treatment. Asparaginase cours-
es were not discontinued in any of the patients with dys-
lipidemia, and 30 weeks of asparaginase exposure were
completed without any other interventions.  
Triglyceride levels were increased in patients receiving
either PEGasparaginase or Erwinia asparaginase, but hyper-
triglyceridemia was more frequent and more severe during
PEGasparaginase treatment. This may be because of the
much higher levels of PEGasparaginase compared to Erwinia
asparaginase. It has been suggested that high triglyceride
levels cause severe pancreatitis.10 However, the highest
triglyceride level among the few patients with pancreatitis
in our study was only 4 mmol/L (grade 2). Of note, we
found the same rate of pancreatitis among patients treated
with Erwinia asparaginase and none of these patients had
hypertriglyceridemia. Furthermore, the asparaginase activi-
ty in the patients with pancreatitis was similar to that in the
patients without pancreatitis. We, therefore, conclude that
the development of pancreatitis is not associated with
hypertriglyceridemia or levels of asparaginase activity. In
addition, we found that triglyceride levels and asparaginase
activity of patients with thrombosis were in the same range
as those of patients without thrombosis. This suggests that
the development of thrombosis is also independent of the
levels of asparaginase activity and triglyceride levels.
Hypertriglyceridemia occurs especially when cortico -
steroids and asparaginase are combined.11,12 The decline in
triglyceride levels in the two patients in our study who
stopped dexamethasone while continuing asparaginase
illustrates this. 
Temporary hypertriglyceridemia grade 3/4 was seen in
about half of the patients receiving PEGasparaginase,
although the triglyceride levels normalized completely in
all patients after they had finished the 30 weeks of
PEGasparaginase infusions. We, therefore, conclude that
there is no need to discontinue or interrupt asparaginase
therapy in the case of hypertriglyceridemia.
The ammonia levels after Erwinia asparaginase therapy
were significantly higher than those after
PEGasparaginase therapy (P<0.001) which seems para-
doxical as PEGasparaginase activity was much greater
than the Erwinia asparaginase activity. However, the differ-
ence can be explained by the higher glutaminase activity
of Erwinia asparaginase, which we recently demonstrated.6
It has been suggested in case reports that ammonia release
could lead to encephalopathy.13-15 Our prospective study,
however, shows that ammonia level was not related to
central neurotoxicity. Even the patients with hyperam-
monemia grade 3/4 did not experience central neurotoxic-
ity and the four patients with central neurotoxicity grade
3/4 did not have higher ammonia levels than those with-
out central neurotoxicity.
The strength of our study was its prospective and longi-
tudinal nature. We closely monitored dyslipidemia and
hyperammonemia during very prolonged asparaginase
courses in two representative centers in the Netherlands.
The limitations lie in the low number of patients experi-
encing pancreatitis, thrombosis or central neurotoxicity.
Particularly, the analyses of patients on Erwinia asparagi-
nase with side effects were based on very small numbers
(Table 1), so conclusions from these analyses should be
interpreted with caution. Larger studies are needed to con-
firm our conclusions.
In conclusion, this study shows that hypertriglyc-
eridemia and hypercholesterolemia grade 3/4 occur fre-
quently, but are temporary and not associated with clini-
cally relevant events and should not, therefore, be consid-
ered a reason for asparaginase treatment modifications.
We show that high levels of asparaginase activity are asso-
ciated with high triglyceride and high cholesterol levels.
However, pancreatitis, thrombosis, and central neurotoxi-
city appear unrelated to asparaginase activity. No associa-
tions were found between pancreatitis and hypertriglyc-
eridemia nor between ammonia level and central neuro-
toxicity. 
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